Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate Alzheimer’s disease.
Category: Cassava Sciences Inc
-
Officials Cast Doubt on a Dementia Drug, but Human Trials Continue
The S.E.C. alleged shortcomings in research said to support the drug, and its developer agreed to a $40 million settlement. Some experts wonder why clinical trials have not been stopped.
-
Executives Depart Cassava, Maker of Disputed Alzheimer’s Drug
The chief executive and a lead scientist stepped down weeks after a federal grand jury filed fraud charges against a research collaborator.
-
Embattled Alzheimer’s Researcher Is Charged With Fraud
Hoau-Yan Wang, a professor at City College, published studies supporting simufilam, now in advanced clinical trials.
-
CUNY Halts Investigation of Alzheimer’s Researcher
Citing questions about the integrity of the process, the university said that “no final action” had been taken.
-
Scientists Investigating Alzheimer’s Drug Faulted in Leaked Report
A professor at the City College of New York engaged in “significant research misconduct,” an investigating committee concluded.